CINECA IRIS Institutional Research Information System

Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study

Iannitto E.;Ferrero S.;Bommier C.;Drandi D.;Ferrante M.;Bouabdallah K.;Carras S.;Gini G.;Camus V.;Mancuso S.;Marcheselli L.;Ferrari A.;Merli M.;Tessoulin B.;Stelitano C.;Beldjord K.;Roti G.;Jardin F.;Castagnari B.;Palombi F.;Baseggio L.;Traverse-Glehen A.;Tripodo C.;Liberati A. M.;Parolini M.;Usai S.;Patti C.;Federico M.;Musso M.;Ladetto M.;Zucca E.;Thieblemont C.

2024-01-01